{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:19:09Z","timestamp":1761808749289,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":114,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG054046","RF1 AG054991"],"award-info":[{"award-number":["R01 AG054046","RF1 AG054991"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s13311-023-01412-1","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T12:02:17Z","timestamp":1691755337000},"page":"911-913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lessons Learned in Time\u2014Is Neurodegeneration Still Something Unpredictable?"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-6777","authenticated-orcid":false,"given":"William T.","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1007\/s13311-023-01412-1_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working G","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1007\/s13311-023-01412-1_bib2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00401-013-1197-3","article-title":"Alzheimer's disease biomarkers: walk with deliberate haste, don't run blithely on?","volume":"126","author":"Hu","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-023-01412-1_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-023-01405-0","article-title":"Anti-amyloid immunotherapies for Alzheimer's disease: a 2023 clinical update","author":"Yadollahikhales","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"17","key":"10.1007\/s13311-023-01412-1_bib4","first-page":"1631","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"Reply N Engl J Med"},{"issue":"5","key":"10.1007\/s13311-023-01412-1_bib5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa2202867","article-title":"Trial of prasinezumab in early-stage Parkinson's disease","volume":"387","author":"Pagano","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1007\/s13311-023-01412-1_bib6","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2203395","article-title":"Trial of cinpanemab in early Parkinson's disease","volume":"387","author":"Lang","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1007\/s13311-023-01412-1_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1007\/s13311-023-01412-1_bib8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat Med"},{"key":"10.1007\/s13311-023-01412-1_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-023-01379-z","article-title":"Fluid and biopsy based biomarkers in Parkinson's disease","author":"Coughlin","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-023-01412-1_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-023-01370-8","article-title":"Charting the next road map for CSF biomarkers in Alzheimer's disease and related dementias","author":"Hu","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-023-01412-1_bib11","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-023-01401-4","article-title":"A real-time neurophysiologic stress test for the aging brain: novel perioperative and ICU applications of EEG in older surgical patients","author":"Berger","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-023-01412-1_bib12","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-023-01410-3","article-title":"The role of clinical assessment in the era of biomarkers","author":"Carlos","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1007\/s13311-023-01412-1_bib13","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-023-01408-x","article-title":"Intersectionality in Alzheimer's disease: the role of female sex and Black American race in the development and prevalence of Alzheimer's disease","author":"Misiura","year":"2023","journal-title":"Neurotherapeutics"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01412-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01412-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:13:44Z","timestamp":1761808424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1878747923019037"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01412-1","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lessons Learned in Time\u2014Is Neurodegeneration Still Something Unpredictable?","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01412-1","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}